<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541915</url>
  </required_header>
  <id_info>
    <org_study_id>3-2018-0066</org_study_id>
    <nct_id>NCT03541915</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate; Postoperative Nausea and Vomiting; Laparoscopic Surgery</brief_title>
  <official_title>The Effect of Intravenous Magnesium Sulfate on Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynecologic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) is commonly accompanied in patients undergoing&#xD;
      surgery under general anesthesia. The patients undergoing laparoscopic gynecologic surgery&#xD;
      have multiple risk factors for developing PONV such as female gender, nonsmoker,&#xD;
      postoperative opioids, and laparoscopic surgery. Thus, it is important to prevent PONV in&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium is a N-methyl-D-aspartate (NMDA) antagonist that is known to be effective in&#xD;
      reducing opioid consumption and controlling postoperative pain. This opioid reducing effect&#xD;
      can be associated with reduction of the incidence of PONV. However, the effect of magnesium&#xD;
      on preventing PONV have not been investigated before. Thus, the investigators hypothesized&#xD;
      that intraoperative infusion of magnesium will be effective in preventing PONV in patients&#xD;
      undergoing laparoscopic gynecologic surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of PONV</measure>
    <time_frame>up to postoperative 2 days</time_frame>
    <description>The incidence of PONV will be measured up to postoperative 2 days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Gynecologic Disease</condition>
  <arm_group>
    <arm_group_label>Mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mg (magnesium sulfate)</intervention_name>
    <description>20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.</description>
    <arm_group_label>Mg group</arm_group_label>
    <other_name>Masi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control (saline)</intervention_name>
    <description>The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gynecologic disease&#xD;
&#xD;
          -  Female patients undergoing laparoscopic gynecologic surgery and receiving&#xD;
             postoperative fentanyl based intravenous patient controlled analgesia (PCA), aged&#xD;
             20-65 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  impaired renal or hepatic function (Glutamic Oxalacetate Transaminase [GOT]/Glutamic&#xD;
             Pyruvate Transaminase [GPT]&gt;50, estimated glomerular filtration rate [eGFR]&lt;60)&#xD;
&#xD;
          -  atrioventricular block, myopathies, diabetes, treated with calcium channel blockers&#xD;
&#xD;
          -  History of receiving antiemetics within 1 day before surgery&#xD;
&#xD;
          -  History of receiving opioids or non-steroidal anti-inflammatory drugs within 1 week of&#xD;
             surgery&#xD;
&#xD;
          -  drugs or alcohol abuse&#xD;
&#xD;
          -  patients treated with isoniazid, chlorpromazine, or digoxin&#xD;
&#xD;
          -  patients who cannot communicated with others or with cognitive dysfunction&#xD;
&#xD;
          -  patients who cannot read informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Do-Hyeong Kim</investigator_full_name>
    <investigator_title>Department of Anesthesiology and Pain Medicine, Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

